Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes
Donna R Palumbo1, Floyd R Sallee2, William E Pelham1
1Drs. Palumbo and McDermott are with University of Rochester; Dr. Sallee is with University of Cincinnati; Dr. Pelham is with State University of New York at Buffalo; Dr. Bukstein is with University of Pittsburgh; and Dr. Daviss is with University of Texas Health Science Center at San Antonio.
Insights
Methylphenidate effectively treats attention-deficit/hyperactivity disorder (ADHD) symptoms. Clonidine showed some benefits but caused more sedation, while methylphenidate offered better efficacy and tolerability for ADHD treatment.
Area of Science:
- Pediatric neurology
- Pharmacology
- Clinical psychology
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
- Treatment options for ADHD include stimulant and non-stimulant medications.
- Understanding the comparative efficacy and safety of different ADHD medications is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of clonidine, alone or with methylphenidate, for ADHD treatment in children.
- To compare the effects of clonidine and methylphenidate on ADHD symptoms and overall functioning.
Main Methods:
- A 16-week randomized, double-blind, placebo-controlled trial involving 122 children (ages 7-12) with ADHD.
- Participants were assigned to receive clonidine, methylphenidate, combination therapy, or placebo using a 2x2 factorial design.
- Efficacy was assessed using teacher and parent rating scales and a global assessment scale.
Main Results:
- Methylphenidate significantly improved ADHD symptoms based on teacher reports, unlike clonidine.
- Clonidine showed benefits on parent-reported symptoms and global functioning but was associated with increased sedation.
- Both treatments were generally well-tolerated, with methylphenidate demonstrating superior efficacy on primary outcome measures.
Conclusions:
- Methylphenidate provides a favorable balance of efficacy and tolerability for treating ADHD in children.
- Clonidine may offer some benefits for ADHD, particularly in parent-reported outcomes, but sedation is a notable side effect.
- Further research may explore optimal dosing and combination strategies for ADHD pharmacotherapy.
Objective:
To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/hyperactivity disorder (ADHD).
Method:
A 16-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 122 children, ages 7 to 12, with any subtype of ADHD, randomly assigned to clonidine, methylphenidate, clonidine in combination with methylphenidate, or placebo according to a 2 x 2 factorial design. In two successive 4-week titration periods, clonidine (or matching placebo) and added methylphenidate (or matching placebo) were adjusted to optimal doses and then continued for 8 weeks. The primary efficacy outcome was changed from baseline to week 16 on the Conners Teachers Abbreviated Symptom Questionnaire. Secondary outcomes included the Conners Abbreviated Symptom Questionnaire for Parents and the Children's Global Assessment Scale.
Results:
On the Conners Teachers Abbreviated Symptom Questionnaire, clonidine was not found to improve ADHD symptoms, whereas subjects treated with methylphenidate showed significant improvement compared to those not treated with methylphenidate. Subjects treated with clonidine had greater improvements on the Conners Abbreviated Symptom Questionnaire for Parents and Children's Global Assessment Scale, but also a higher rate of sedation compared with subjects not treated with clonidine.
Conclusions:
Based on the Conners Teachers Abbreviated Symptom Questionnaire, methylphenidate offers the best combination of efficacy and tolerability for ADHD. Clonidine was well tolerated despite the frequency of sedation and did offer some benefit.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:28Drug Therapy
Antianxiety Medications
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:30Oppositional Defiant Disorder
Diagnostic Criteria and...